Illumina, Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications i…
Medical - Diagnostics & Research
US, San Diego [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -2.69 | 454.50 | 467.06 | |
| Graham Fair Price | -15.47 | 25.36 | 30.00 | |
| PEG | 254.36 | 1.45 | 0.41 | |
| Price/Book | -4.50 | 3.68 | 3.85 | |
| Price/Cash Flow | 299.87 | 514.69 | 128.72 | |
| Prices/Earnings | -33.14 | -41.87 | -31.45 | |
| Price/Sales | -0.61 | 19.61 | 19.73 | |
| Price/FCF | 299.87 | 514.69 | 128.72 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 3.04 | 0.62 | 0.60 | |
| Operating Margin | -7.93 | -0.05 | -0.05 | |
| ROA | 27.90 | -0.01 | -0.02 | |
| ROE | -0.03 | -0.02 | 28.27 | |
| ROIC | < 0.005 | < 0.005 | -14.37 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | 0.03 | -81.95 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.92 | -0.04 | -96.20 | |
| EPS QOQ | 0.77 | 0.29 | -62.43 | |
| FCF QOQ | 0.83 | -0.76 | -8.21 | |
| Revenue QOQ | < 0.005 | -0.04 | 1429.23 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 118.19 | 128.51 | 8.73 | |
| Days Sales Outstanding (DSO) | 60.32 | 54.37 | -9.87 | |
| Inventory Turnover | 0.76 | 0.70 | -8.03 | |
| Debt/Capitalization | 0.22 | 0.22 | 0.20 | |
| Quick Ratio | 1.15 | 1.20 | 4.09 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 36.13 | 36.06 | -0.19 | |
| Cash | 6.63 | 7.01 | 5.79 | |
| Capex | -0.32 | -0.23 | 29.41 | |
| Free Cash Flow | 1.08 | 0.26 | -76.16 | |
| Revenue | 7.06 | 6.77 | -4.10 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Weak